Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Refractory Solid Tumors
NCT02691793Phase 4Completed
- Sponsor
- Samsung Medical Center
- Start
- Nov 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sunitinib in solid tumor, sponsored by Samsung Medical Center. Primary endpoint: Progression-Free Survival at 24 months. Started Nov 2017; status: completed.
02
Drugs
sunitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02691793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691793.